A Phase 3 interventional study of Azithromycin and Placebo in Chronic Obstructive Pulmonary Disease, sponsored by Wim Janssens. Terminated at 20 sites in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-09-05.
Sponsored by Wim Janssens · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing azithromycin in Pulmonary Disease, Chronic Obstructive — 1 open to participants now, 1 under way, none of them phase 3. Azithromycin · Pulmonary Disease, Chronic Obstructive.
Among the 17 studies testing azithromycin in Pulmonary Disease, Chronic Obstructive, this one is the 6th largest by enrollment, is one of 3 that started in 2014, is one of 6 in phase 3, and was the 9th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →1 of the 17 studies testing azithromycin in Pulmonary Disease, Chronic Obstructive is open now, in 1 country. Recruiting first, the newest first:
Dr Ian B Wilkinson · Sites in United Kingdom
Ages 40+
By country, each count listing its studies:
Azithromycin: first FDA approval 1991 (ZITHROMAX). What it is approved for, and how studies give it, is on its page →
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 301 is above the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 92 across the 17 interventional studies. Of the 13 that completed or were terminated, 1 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 17 have an industry lead sponsor. The 10 most frequent:
Wim Janssens is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Wim Janssens has 5 studies filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing azithromycin in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This project (funded by the IWT-TBM program) will organize a randomized placebo-controlled multicenter intervention trial in 500 COPD patients to study the effectiveness and safety of azithromycin therapy in the acute setting of COPD exacerbations requiring hospital admission. Although long-term use of azithromycin is proven effective to prevent exacerbations, inherent risks outweigh the benefits. By reducing the dose and duration of the azithromycin treatment and by restricting the treatment to acute periods with highest risk for treatment failure, benefits may counterbalance potential side effects, which may result in a new treatment strategy for these acute events.
The present study is designed by the services of respiratory medicine of the Leuven and Ghent University hospitals but will run in total in 17 different large hospitals in Belgium, of which 12 are located in Flanders.
In this 9 month, randomized, placebo-controlled, parallel-group, multicenter intervention trial, 500 patients will be randomly assigned (1:1 ratio) to receive either azithromycin or placebo on top of standard therapy in the acute treatment of COPD exacerbations requiring hospitalization. The study drug (azithromycin or placebo) will be initiated and uploaded within 48 hours after hospital admission (500mg once a day for 3 days) and subsequently administered for a prolonged period of 3 months at a lower maintenance dose (250mg every 2 days). An additional follow-up period of 6 months without study drug will be foreseen to study relapse after study drug withdrawal.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
N = 250 * From day 1 up to and including day 3: 500 mg azithromycin PO once a day * From day 4 up to and including day 90: 250 mg azithromycin PO once every 2 days
Drug: Azithromycin
N = 250 * From day 1 up to and including day 3: 500 mg placebo PO once a day * From day 4 up to and including day 90: 250 mg placebo PO once every 2 days
Drug: Placebo
* From day 1 up to and including day 3: 500 mg azithromycin PO once a day * From day 4 up to and including day 90: 250 mg azithromycin PO once every 2 days
Also known as: Azitromcyine CF, ATC code: J01FA10
* From day 1 up to and including day 3: 500 mg placebo PO once a day * From day 4 up to and including day 90: 250 mg placebo PO once every 2 days
Also known as: Inactive substance
Time to clinical failure
Clinical failure is a composite endpoint as multiple clinical interventions may indicate that an initiated therapy is failing. Clinical failure is defined as the composite of death, treatment intensification (additional dose of systemic steroids, switch antibiotics for respiratory reasons or new course of systemic steroids and/or antibiotics) and step up in hospital care for respiratory reasons (from ward to ICU during index event, or from home to ward or ICU (new admission) after discharge). Primary outcome measure will also be analysed in following subgroups as an exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use
Time frame: Will be assessed between day 1 (from 1 hour after first drug intake) till day 90 (24 hours after last study drug intake)
Number of clinical failures up to Day 90 (key secondary #1)
Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III * ICS use vs no ICS use
Time frame: Will be assessed on day 90 (last day of treatment phase)
COPD Assessment Test (CAT) score at Day 90 (key secondary #2)
Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use
Time frame: Will be assessed on day 90 (last day of treatment phase)
Total days of additional/prolonged systemic steroid use at Day 90 (key secondary #3)
Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use
Time frame: Will be assessed on day 90 (last day of treatment phase)
Number of clinical failures up to Day 270
Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III * ICS use vs no ICS use
Time frame: Will be assessed on day 270 (last day of follow-up phase)
Time to clinical failure up to Day 90 and up to Day 270
Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use
Time frame: Will be assessed on day 90 (last day of treatment phase) and day 270 (last day of follow-up phase)
Time to new exacerbation within 90 and within 270 days
A new exacerbation is defined as the composite of new course of systemic steroids and/or antibiotics, and hospitalization for respiratory reasons, all after the index event. Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use
Time frame: Will be assessed on day 90 (last day of treatment phase) and day 270 (last day of follow-up phase)
Number of new exacerbations up to 90 days and up to 270 days
Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use
Time frame: Will be assessed on day 90 (last day of treatment phase) and day 270 (last day of follow-up phase)
Total days of hospital days within 90 and within 270 days
Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use
Time frame: Will be assessed on day 90 (last day of treatment phase) and day 270 (last day of follow-up phase)
Total days in intensive care within 90 and within 270 days
Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use
Time frame: Will be assessed on day 90 (last day of treatment phase) and day 270 (last day of follow-up phase)
Quality of Life - 5 Dimensions (EQ5D) score at Day 90 and at Day 270
Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use
Time frame: Will be assessed on day 90 (last day of treatment phase) and day 270 (last day of follow-up phase)
COPD Assessment Test (CAT) score at Day 270
Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use
Time frame: Will be assessed on day 270 (last day of follow-up phase)
Modified Medical Research Council (mMRC) score at Day 90 and Day 270
Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use
Time frame: Will be assessed on day 90 (last day of treatment phase) and day 270 (last day of follow-up phase)
Speech, Spatial and Qualities of Hearing (SSQ5) score at Day 90 and Day 270
Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use
Time frame: Will be assessed on day 90 (last day of treatment phase) and day 270 (last day of follow-up phase)
Pre-bronchodilator forced expiratory volume in 1 second (FEV1) at Day 90 and Day 270
Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use
Time frame: Will be assessed on day 90 (last day of treatment phase) and day 270 (last day of follow-up phase)
Total dose of additional/prolonged systemic steroids at Day 270
Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use
Time frame: Will be assessed on day 270 (last day of follow-up phase)
Total days of additional/prolonged systemic steroid use at Day 270
Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use
Time frame: Will be assessed on day 270 (last day of follow-up phase)
Total days of non-study antibiotic use at Day 90 and Day 270
Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use
Time frame: Will be assessed on day 90 (last day of treatment phase) and day 270 (last day of follow-up phase)
Number of home physician contacts at Day 90 and Day 270
Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use
Time frame: Will be assessed on day 90 (last day of treatment phase) and day 270 (last day of follow-up phase)
Average cost of hospitalization at Day 90 and Day 270 including the index hospitalization
Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use
Time frame: Will be assessed on day 90 (last day of treatment phase) and day 270 (last day of follow-up phase)
Time to death within 90 and within 270 days
Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use
Time frame: Will be assessed on day 90 (last day of treatment phase) and day 270 (last day of follow-up phase)
Time to first treatment intensification within 90 and within 270 days
Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use
Time frame: Will be assessed on day 90 (last day of treatment phase) and day 270 (last day of follow-up phase)
Time to first step up in hospital care for respiratory reasons within 90 and within 270 days
Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use
Time frame: Will be assessed on day 90 (last day of treatment phase) and day 270 (last day of follow-up phase)
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2014 to primary completion in Oct 2017, 38 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Azithromycin
Pulmonary Disease, Chronic Obstructive →
Wim Janssens